Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Nevirapine (compound)

Name: Nevirapine
PubChem Compound ID: 4463
Description: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV infection and AIDS.
Molecular formula: C15H14N4O
Molecular weight: 266.298 g/mol
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; Nevirapine; 129618-40-2; Dipyridodiazepinone Nevirapine; AIDS-005653; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; Viramune; NVP; BIRG 587; Viramune (TN).
show more »
Name: Nevirapine
Name (isomeric): DB00238
Drug Type: small molecule
Description: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV infection and AIDS.
Brand: Viramune
Category: Anti-HIV Agents, Nonnucleoside Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitors
CAS number: 129618-40-2
Indication: For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and i...
show more »
Mechanism of Action: Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.
Absorption: 90% (absolute bioavailability 93 ± 9%)
Protein binding: 60%
Biotransformation: Hepatic. In vivo studies in humans and in vitro studies with human liver microsomes have shown that nevirapine is extensively biotransformed via cytochrome P450 3A4 metabolism to several hydroxylated metabolites.
Route of elimination: Thus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. Only a small fraction (<5%) of the radioactivity in urine (representing <3% of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.
Half Life: 45 hours
Toxicity: Symptoms of overdose include edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonaryinfiltrates, rash, vertigo, vomiting, and weight decrease.
Affected organisms: Human Immunodeficiency Virus
Food interaction:
Avoid alcohol.
Take without regard to meals.
Drug interaction:
AtazanavirNevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atazanavir by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atazanavir if nevirapine is initiated, discontinued or dose changed.
TelithromycinNevirapine may decrease the plasma concentration of Telithromycin. Consider alternate therapy.
TrazodoneThe CYP3A4 inducer, Nevirapine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nevirapine is initiated, discontinued or dose changed.
NelfinavirNevirapine may decrease the effect of nelfinavir.
St. John's WortSt. John's Wort decreases nevirapine effect
show more »